An observational study in Gastrointestinal Neoplasms, sponsored by Ankara Etlik City Hospital. Completed at 3 sites in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Ankara Etlik City Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 21 studies in Gastrointestinal Neoplasms with a site in Turkey — 3 open to participants now, 5 under way, 1 of them phase 3. Gastrointestinal Neoplasms · Turkey.
Among the 21 studies in Gastrointestinal Neoplasms with a site in Turkey, this one is the 2nd largest by enrollment of the 13 observational ones that give a count, is one of 4 that started in 2025, is one of 13 observational ones, and was the 13th registered.
698 studies on the registry are indexed under Gastrointestinal Neoplasms; 211 are open to participants now.
Browse Gastrointestinal Neoplasms studies →3 of the 21 studies in Gastrointestinal Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:
Van Training and Research Hospital · Sites in Turkey
Ages 60+
Van Training and Research Hospital · Sites in Turkey
Ages 60+
Artvin Coruh University · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 160 Gastrointestinal Neoplasms studies recruiting now, 121 (76%) set no upper age limit and 19 (12%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
21 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 4 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 198 is close to the median of 200 across 168 observational studies indexed under Gastrointestinal Neoplasms.
Median enrollment 140 across the 7 interventional studies, 100 across the 13 observational. Of the 14 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 21 have an industry lead sponsor. The 10 most frequent:
Ankara Etlik City Hospital is the lead sponsor of 180 studies on the registry; 77 are open to participants now.
Ankara Etlik City Hospital has 3 studies filed under Gastrointestinal Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Gastrointestinal Neoplasms with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07383935Artvin Coruh UniversityStress Ball Use During Chemotherapy in Gastrointestinal Cancer Patients | 2027-02-03 |
| NCT07815392Van Training and Research HospitalPreoperative Frailty and Postoperative Outcomes in Older Patients Undergoing Surgery for Gastrointestinal Cancer | 2027-06-01 |
| NCT07817758Van Training and Research HospitalPreoperative Sarcopenia and Postoperative Outcomes in Older Patients With Gastrointestinal Cancer | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 21 studies in Gastrointestinal Neoplasms with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This prospective, single-center, non-interventional observational cohort study evaluated longitudinal changes in sleep quality, depressive symptoms, and health-related quality of life among adults receiving fluoropyrimidine-based adjuvant chemotherapy for nonmetastatic gastrointestinal cancers.
A total of 198 participants receiving either FOLFOX or CAPEOX were enrolled at Ankara Etlik City Hospital between May 30, 2025, and March 30, 2026. Longitudinal patient-reported outcomes included the Pittsburgh Sleep Quality Index (PSQI), Beck Depression Inventory (BDI), and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).
The longitudinal assessment framework included baseline, month-3, and month-6 evaluations. In addition to describing changes in sleep, depressive symptoms, and quality of life, analyses examined the temporal indirect association between baseline sleep disturbance and month-6 global health status/quality of life through month-3 depressive symptoms.
Secondary analyses evaluated nutritional status, anthropometric measures, and body composition using clinically available computed tomography examinations. Treatment-regimen comparisons were observational and did not involve investigator-directed treatment assignment.
The final follow-up data cutoff was September 30, 2026.
This prospective, single-center observational study was conducted in the Medical Oncology Department of Ankara Etlik City Hospital, Türkiye, among adults with histologically confirmed nonmetastatic gastrointestinal malignancies who were scheduled to receive fluoropyrimidine-based adjuvant chemotherapy.
Participants received standard-of-care treatment with either FOLFOX, an intravenous fluorouracil-based regimen, or CAPEOX, an oral capecitabine-based regimen combined with intravenous oxaliplatin. Treatment allocation was determined by routine clinical care rather than research assignment.
The final cohort comprised 198 participants. Recruitment began on May 30, 2025, and ended on March 30, 2026. The longitudinal assessment schedule included baseline, month 3, and month 6, with a final follow-up data cutoff of September 30, 2026.
Sleep quality was evaluated using the PSQI, depressive symptoms using the BDI, and health-related quality of life using the EORTC QLQ-C30. The principal quality-of-life domains evaluated included global health status/quality of life, physical functioning, and fatigue.
Longitudinal analyses characterized changes in patient-reported outcomes during adjuvant chemotherapy. A longitudinal path model examined the association between baseline PSQI and month-6 global health status/quality of life through month-3 depressive symptom burden. The reciprocal temporal association was also evaluated. These models were interpreted as observational associations rather than evidence of causal mediation.
Additional analyses evaluated the relationships of baseline and longitudinal body-composition measurements with subsequent health-related quality of life. Skeletal muscle index and muscle attenuation were obtained from routine clinically available computed tomography examinations; no additional CT examinations were required solely for research purposes.
Nutritional screening, body weight, body mass index, treatment-related factors, and relevant baseline clinical characteristics were recorded. Exploratory analyses examined longitudinal differences according to chemotherapy regimen.
The study did not modify standard oncological treatment. Patients requiring additional assessment for clinically significant sleep disturbances or psychological symptoms could be referred for appropriate clinical evaluation.
The original ClinicalTrials.gov registration emphasized comparisons of oral versus intravenous fluoropyrimidine-based regimens and early PSQI/BDI assessments. Subsequent registration updates should be interpreted in conjunction with the dated ethics-approved study protocol, the actual longitudinal assessment schedule, and the publicly available registration history.
The criteria were revised on the registry on Oct 13, 2026. See what changed
The study population comprised 198 consecutive adult patients with histologically confirmed stage II-III gastric or colorectal cancer receiving standard-of-care adjuvant FOLFOX (n=102) or CAPEOX (n=96) at Ankara Etlik City Hospital, Türkiye. Participants were prospectively enrolled between May 30, 2025, and March 30, 2026. Sleep quality, depressive symptoms, and health-related quality of life were assessed at baseline, month 3, and month 6. Nutritional and anthropometric measures were recorded, and body composition was evaluated using available routine CT examinations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pre-existing selective serotonin reuptake inhibitor (SSRI) therapy was not considered an exclusion criterion solely on the basis of medication class. Baseline SSRI use was documented and accounted for in the statistical analyses.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with nonmetastatic gastrointestinal cancer receiving standard-of-care adjuvant chemotherapy with CAPEOX (oral capecitabine plus intravenous oxaliplatin). This observational cohort comprised 96 participants. Treatment selection was determined by routine clinical practice, without investigator-directed treatment assignment.
Patients with nonmetastatic gastrointestinal cancer receiving standard-of-care adjuvant chemotherapy with FOLFOX (intravenous fluorouracil, leucovorin, and oxaliplatin). This observational cohort comprised 102 participants. Treatment selection was determined by routine clinical practice, without investigator-directed treatment assignment.
Longitudinal Indirect Association Between Sleep Disturbance, Depressive Symptoms, and Quality of Life
The indirect association of baseline Pittsburgh Sleep Quality Index (PSQI) score with month-6 EORTC QLQ-C30 global health status/quality-of-life score through month-3 Beck Depression Inventory (BDI) score is estimated using an adjusted longitudinal path model. The indirect association is expressed as the product of regression coefficients (a×b), with a bootstrap 95% confidence interval.
Time frame: Baseline, Month 3, and Month 6 (up to 6 months after chemotherapy initiation).
Longitudinal Change in Depressive Symptoms Assessed by the Beck Depression Inventory
Depressive symptoms are assessed using the Beck Depression Inventory (BDI), with total scores ranging from 0 to 63. Higher scores indicate greater depressive symptom burden. Changes in BDI total scores are evaluated across baseline, month 3, and month 6 using longitudinal mixed-effects models.
Time frame: Baseline, Month 3, and Month 6.
Longitudinal Change in EORTC QLQ-C30 Global Health Status/Quality of Life
Global health status/quality of life is assessed using the EORTC QLQ-C30 global health status scale, ranging from 0 to 100. Higher scores indicate better quality of life. Changes over time are evaluated using longitudinal mixed-effects models.
Time frame: Baseline, Month 3, and Month 6.
Longitudinal Changes in Physical Functioning and Fatigue
Physical functioning and fatigue are evaluated using the corresponding EORTC QLQ-C30 scales (0-100). Higher physical-functioning scores represent better functioning, whereas higher fatigue scores indicate greater symptom burden. Longitudinal changes are assessed across three scheduled visits.
Time frame: Baseline, Month 3, and Month 6.
Longitudinal Change in Skeletal Muscle Index (SMI)
Skeletal muscle index (SMI, cm²/m²) is calculated from skeletal muscle cross-sectional area at the third lumbar vertebral level (L3), measured using clinically available computed tomography (CT) images and normalized to height squared. Longitudinal changes in SMI and its associations with month-6 health-related quality of life are evaluated. No additional CT scans are performed for research purposes.
Time frame: Baseline, Month 3, and Month 6 (when routine CT images are available).
Longitudinal Change in Skeletal Muscle Attenuation
Skeletal muscle attenuation is measured in Hounsfield units (HU) from L3 skeletal muscle segmentation on routine CT images. Longitudinal changes in muscle attenuation and its associations with month-6 global health status/quality of life, physical functioning, and fatigue are evaluated. Higher attenuation generally indicates lower intramuscular fat content.
Time frame: Baseline, Month 3, and Month 6 (when routine CT images are available).
Plan to share: No — Individual participant data (IPD) will not be shared due to local data protection regulations, ethical restrictions, and the absence of prior consent for data sharing.
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Apr 2026, 10 months.
Of 79 non-industry observational studies under Gastrointestinal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 14. This study's 10 months is below that.
Counting every sponsor, half of 88 studies reached it within 43 months; a quarter within 16 and three quarters within 102.
Start moved once since we started tracking on Sep 25, 2026: Jun 2025 → May 2025, on Oct 13, 2026.
Primary completion moved twice since we started tracking on Sep 25, 2026: Oct 2025 → Apr 2026, last on Nov 13, 2026.
Completion moved once since we started tracking on Sep 25, 2026: Apr 2026 → Sep 2026, on Oct 13, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.